Navigation Links
Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting
Date:7/15/2009

velopment of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the abstracts and materials presented at this meeting with respect to REOLYSIN, the Company's expectations related to the results of trials investigating delivery of REOLYSIN, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
4. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
5. Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results
6. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
7. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
8. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
9. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
10. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
11. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014 AACC, a global scientific and ... medicine, unveiled an updated brand identity today that reflects ... the changing healthcare environment and continue to do what ... patients get the care they need. ... play an essential role in saving lives and making ...
(Date:8/1/2014)... CHICAGO , Aug. 1, 2014 The  ... increasing the number and success rate of early-stage life ... today that it has awarded 15 grants to help ... AdvaMed 2014: The MedTech Conference   in ... leading MedTech conference in North America ...
(Date:8/1/2014)... , Aug. 1, 2014 Research and ... "Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market ... http://photos.prnewswire.com/prnh/20130307/600769 Single Nucleotide Polymorphism ... variations of SNPs in the genome of various species. ... SNP genotyping and analysis technology can analyze thousands of ...
(Date:8/1/2014)... 2014 BCC Research ( http://www.bccresearch.com ) ... TECHNOLOGIES AND GLOBAL MARKETS , that the global market ... grow to nearly $38.8 billion by 2018, with a ... aptamer delivery category, the fastest moving segment of the ... The field of RNAi therapeutics has shown tremendous growth ...
Breaking Biology Technology:AACC Debuts Refreshed Brand Identity 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 4Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3
... fields and tiny iron-bearing particles to drive healthy cells ... in animals, may lead to a new method of ... organs in people. , The study team, led by ... of Pediatric Cardiology at The Childrens Hospital of Philadelphia, ...
... ALTO, Calif., Jan. 7 Telik, Inc. (Nasdaq: ... overview at the,26th Annual JPMorgan Healthcare Conference in San ... Pacific time (10:30 a.m. Eastern,time). A live and archived ... website, http://www.telik.com ., Telik, Inc. of Palo ...
... Potential Blockbuster Product for High Risk Cardiovascular ... ... Calif., Jan. 7 ,Genzyme Corp. (Nasdaq: GENZ ) and Isis ... a major strategic alliance in which,Genzyme will develop and commercialize mipomersen, ...
Cached Biology Technology:Researchers use magnetism to target cells to animal arteries 2Researchers use magnetism to target cells to animal arteries 3Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 2Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 3Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 4Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 5Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 6Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 7
(Date:7/31/2014)... found to be a key gene responsible for hearing in ... cells of the inner ear that contracts and expands rapidly ... phonograph horn, amplify sound waves to make hearing more sensitivity. ... advanced online edition of Molecular Biology and Evolution , ... independently evolved to play a critical role in the ultrasonic ...
(Date:7/31/2014)... Fla. --- By tracing nearly 3,000 genes to ... University of Florida scientists have created an extensive ... use large-scale, next-generation DNA sequencing. , Among ... closely related to small moths than to large ... butterflies evolved. The study also found that some ...
(Date:7/31/2014)... DARIEN, IL Researchers who studied 100 twin pairs have ... function normally on less than six hours of sleep per ... resistance to the effects of sleep deprivation. , Results show ... BHLHE41 gene had an average nightly sleep duration of ... than the non-carrier twin, who slept for about six hours ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Study of twins discovers gene mutation linked to short sleep duration 2
... 2011)Regular exercise has proven benefits in preventing and ... tough to meet the American Diabetes Association guidelines of ... A new study, conducted by researchers at McMaster University, ... a small proof-of-principle study in eight type 2 diabetes ...
... How to manage waste has become one of the ... of electrical and electronic equipment that is designed, manufactured and ... and at times highly toxic. Up to 1,200 companies working ... to 10% of their recycling costs thanks to this new ...
... plant growth enhancers are becoming increasingly sought-after. Many ... with limited research capabilities, have not been tested ... effectiveness been documented by scientific data. Researchers from ... effect of Tea Seed Powder (TSP), a saponin-rich ...
Cached Biology News:Exercising harder -- and shorter -- can help Type 2 diabetes 2Exercising harder -- and shorter -- can help Type 2 diabetes 31,200 recycling sector companies will save up to 10 percent thanks to a new system developed by Tecnalia 2Plant growth affected by tea seed powder 2
A univariate (peak height or area) quantitative multi-component analysis package....
... The micro 1 is a dramatic breakthrough ... from 1mL with 10nL resolution, the micro 1 ... benchtop dispenser. And, the micro 1 never needs ... , Touch Screen programming on an LCD Display ...
... microscopes offer all of the features of ... Equipped with Koehler illumination, a centerable condenser ... B3 is the workhorse of Motic's range ... the need for re-focusing following a change ...
... Dye Primer Manual Cycle Sequencing Kit is ... primers and high-resolution fluorescence scanners. Sequencing reactions ... slab gel electrophoresis and scanning of the ... The kit components have been optimized ...
Biology Products: